Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Photo of Debra Tonetti

Debra Tonetti


Professor of Pharmacology, College of Pharmacy - Pharmaceutical Sciences
Leader, Breast Cancer Working Group, UI Cancer Center, University of Illinois at Chicago

Related Sites:

Teaching and Supervision Heading link

PSCI Ph.D. Thesis Research (PSCI 599), 8/21/2023 – 12/1/2023
Pharm Sciences Rotation (PSCI 592), 8/21/2023 – 12/1/2023
Undergrad Res Exp Pharm Sci (PSCI 300), 8/21/2023 – 12/1/2023
PDAT 9: Hematology/Oncology (PHAR 509), 1/9/2023 – 4/28/2023
Undergrad Res Pharm Sci (PSCI 380), 1/9/2023 – 4/28/2023
Special Proj Pharm Sci (PSCI 390), 1/9/2023 – 4/28/2023
PDAT 9: Hematology/Oncology (PHAR 509), 1/9/2023 – 4/28/2023
PDAT 9: Hematology/Oncology (PHAR 509), 1/9/2023 – 4/28/2023
PDAT 9: Hematology/Oncology (PHAR 509), 1/9/2023 – 4/28/2023

Selected Grants

Finding cancer vulnerability through analysis of tolerant cell populations, Amer Lung Assn of Metropolitan Chicago., 7/1/2022 - 6/30/2024, Obligated Amount: $200000; Anticipated Amount: $200000

Estrogen Receptor and NFkB Crosstalk in Breast Cancer, National Institutes of Health (National Cancer Institute)., 2/1/2022 - 1/31/2027, Obligated Amount: $944421; Anticipated Amount: $2384909

Breast cancer virotherapy, National Institutes of Health (National Cancer Institute)., 4/1/2021 - 3/31/2024, Obligated Amount: $406658; Anticipated Amount: $411143

Targeting Serine Auxotrophy in Luminal Breast Cancer, National Institutes of Health (National Cancer Institute)., 3/1/2021 - 2/28/2026, Obligated Amount: $1395593; Anticipated Amount: $1798445

A Novel Biomarker for TTC-352 Therapy Development., 5/15/2019 - 4/30/2020, Obligated Amount: $1000000; No Anticipated Amount Set

A novel biomarker for TTC 352 cancer therapy development, University of Illinois DPI Seed Funding Program., 5/1/2019 - 4/30/2020, Obligated Amount: $100000; Anticipated Amount: $100000

A Novel BET Inhibitor for Breast Cancer Combinatiion Therapy, Chicago Biomedical Consortium., 1/1/2019 - 12/31/2019, Obligated Amount: $100000; Anticipated Amount: $100000

Development of PET Probe for ER+ Breast Cancer, UICentre-CCTS Inception Grant., 7/1/2018 - 6/30/2019, Obligated Amount: $12500; Anticipated Amount: $12500

Discovery of New Partners for Combination Therapy with G1T48, G1 Therapeutics Inc., 6/1/2017 - 5/31/2018, Obligated Amount: $350000; Anticipated Amount: $350000

Selected Publications

Means-Powell, Julie A, Mayer, Ingrid A, Ismail-Khan, Roohi, Del Valle, Luis, Tonetti, Debra, Abramson, Vandana G, Sanders, Melinda S, Lush, Richard M, Sorrentino, Claudia, Majumder, Samarpan, Miele, Lucio. (2022). A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC). Clinical Breast Cancer, 22, (2), 103-114. doi:10.1016/j.clbc.2021.10.013.

Abderrahman, Balkees, Maximov, Philipp Y, Curpan, Ramona F, Fanning, Sean W, Hanspal, Jay S, Fan, Ping, Foulds, Charles E, Chen, Yue, Malovannaya, Anna, Jain, Antrix, Xiong, Rui, Greene, Geoffrey L, Tonetti, Debra A, Thatcher, Gregory RJ, Jordan, V Craig. (2021). Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer. Molecular Cancer Therapeutics, 20, (1), 11-25. doi:10.1158/1535-7163.mct-20-0563.

, . (2020). Correction to “Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer”. Molecular Pharmacology, 98, (4), 528-528. doi:10.1124/molpharm.120.000054err.

Dudek, Arkadiusz Z, Liu, Li C, Fischer, James H, Wiley, Elizabeth L, Sachdev, Jasgit C, Bleeker, Jonathan, Hurley, Randolph W, Tonetti, Debra A, Thatcher, Gregory RJ, Venuti, Robert P, O’Regan, Ruth M. (2020). Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. Breast Cancer Research and Treatment, 183, (3), 617-627. doi:10.1007/s10549-020-05787-z.

Li, Yangfeng, Zhao, Jiong, Gutgesell, Lauren M, Shen, Zhengnan, Ratia, Kiira, Dye, Katherine, Dubrovskyi, Oleksii, Zhao, Huiping, Huang, Fei, Tonetti, Debra A, Thatcher, Gregory RJ, Xiong, Rui. (2020). Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. Journal of Medicinal Chemistry, 63, (13), 7186-7210. doi:10.1021/acs.jmedchem.0c00456.

Andreano, Kaitlyn J, Wardell, Suzanne E, Baker, Jennifer G, Desautels, Taylor K, Baldi, Robert, Chao, Christina A, Heetderks, Kendall A, Bae, Yeeun, Xiong, Rui, Tonetti, Debra A, Gutgesell, Lauren M, Zhao, Jiong, Sorrentino, Jessica A, Thompson, Delita A, Bisi, John E, Strum, Jay C, Thatcher, Gregory RJ, Norris, John D. (2020). G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment, 180, (3), 635-646. doi:10.1007/s10549-020-05575-9.

Abderrahman, B, Maximov, PY, Curpan, RF, Hanspal, JS, Fan, P, Xiong, R, Tonetti, DA, Thatcher, GRJ, Jordan, VC. (2020). Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer (vol 98, pg 364, 2020). MOLECULAR PHARMACOLOGY, 98, (4), 528-528.

Lu, Yunlong, Gutgesell, Lauren M, Xiong, Rui, Zhao, Jiong, Li, Yangfeng, Rosales, Carlo I, Hollas, Michael, Shen, Zhengnan, Gordon-Blake, Jesse, Dye, Katherine, Wang, Yueting, Lee, Sue, Chen, Hu, He, Donghong, Dubrovyskyii, Oleksii, Zhao, Huiping, Huang, Fei, Lasek, Amy W, Tonetti, Debra A, Thatcher, Gregory RJ. (2019). Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer. Journal of Medicinal Chemistry, 62, (24), 11301-11323. doi:10.1021/acs.jmedchem.9b01580.

Xiong, R, Li, Y, Zhao, J, Huang, F, Shen, Z, Lu, Y, Gutgesell, L, Tonetti, DA, Thatcher, GRJ. (2019). 502P Basic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer. Annals of Oncology, 30, v189. doi:10.1093/annonc/mdz244.064.

Education

Degrees:
Doctor of Philosophy, Loyola University Chicago, United States, 1990
Master of Science, Loyola University Chicago, United States, 1985
Bachelor of Science, Northern Illinois University, United States, 1980

Postgraduate Training:
Enrico Fermi Postdoctoral Fellow, Argonne National Laboratory, United States, 1994